Program
enpatoran
Also written as “M5049”, “Enpatoran” and “Enpatoran low dose”.
Its studies are mostly in Lupus Erythematosus, Systemic · Lupus Erythematosus, Cutaneous · Dermatomyositis · Renal Insufficiency · COVID-19, led by Merck KGaA, Darmstadt, Germany.
Furthest: phase 3, since Jan 9, 202612 company-led studies, 4 open or runningNext primary completion: Aug 12, 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck KGaA, Darmstadt, Germany | 124 open or running | phase 3since Jan 9, 2026 | Sep 17, 2018 | Aug 12, 2028phase 2 · NCT05540327 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 17, 2018First study: phase 1 study in HealthyFirst studyNCT03676322 · 96 enrolled · Germany
- Jun 25, 2020Phase 2 study in COVID-19NCT04448756 · 149 enrolled · United States, Brazil, Philippines
- Nov 23, 2020Phase 1 study in Lupus Erythematosus, SystemicNCT04647708 · 25 enrolled · Bulgaria, Germany, Moldova, Republic of and more
- May 5, 2021Phase 1 study in HealthyNCT04880213 · 36 enrolled · United Kingdom
- Dec 8, 2021Phase 2 study in Lupus Erythematosus, SystemicNCT05162586 · 456 enrolled · United States, Argentina, Australia and more
- Sep 12, 2022Phase 2 study in Lupus Erythematosus, SystemicNCT05540327 · 381 enrolled · United States, Argentina, Australia and more
- Dec 6, 2022Phase 2 study in DermatomyositisNCT05650567 · 20 enrolled · United States, Czechia, Greece and more
- Sep 6, 20242 phase 1 studiesNCT06589726, NCT06589713
- Jan 9, 20262 phase 3 studiesPhase 3 reachedNCT07332481, NCT07355218
- Sep 18, 2026Phase 3 study in Lupus Erythematosus, SystemicNCT07840287 · 404 planned · United States
Ahead
- Aug 12, 2028Primary completion: phase 2 study in Lupus Erythematosus, SystemicNCT05540327
- May 24, 2029Primary completion: phase 3 study in Lupus Erythematosus, SystemicNCT07332481
- May 25, 2029Primary completion: phase 3 study in Lupus Erythematosus, CutaneousNCT07355218
- Sep 1, 2031Primary completion: phase 3 study in Lupus Erythematosus, SystemicNCT07840287
TargetBeta
“Toll-like receptor 8 antagonist; Toll-like receptor 7 antagonist”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| resiquimodrule | Staidson (Beijing) Biopharmaceuticals | phase 3 | 14 |
| afimetoranrule | Bristol-Myers Squibb | phase 3 | 12 |
Studies
All 12 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07840287Lupus Erythematosus, Systemic · United States | 3 | Recruiting | Sep 1, 2031 | 404 |
| NCT07355218Lupus Erythematosus, Cutaneous · United States, Australia, Belgium and more | 3 | Recruiting | May 25, 2029 | 202 |
| NCT07332481Lupus Erythematosus, Systemic · United States, Australia, Belgium and more | 3 | Recruiting | May 24, 2029 | 202 |
| NCT06589726Healthy · Germany | 1 | Completed | Dec 2, 2024 | 40 |
| NCT06589713Renal Insufficiency · Germany | 1 | Completed | Apr 13, 2026 | 34 |
| NCT05650567Dermatomyositis · United States, Czechia, Greece and more | 2 | Terminated | Jun 25, 2025 | 20 |
| NCT05540327Lupus Erythematosus, Systemic · United States, Argentina, Australia and more | 2 | Active, not recruiting | Aug 12, 2028 | 381 |
| NCT05162586Lupus Erythematosus, Systemic · United States, Argentina, Australia and more | 2 | Completed | Nov 20, 2024 | 456 |
| NCT04880213Healthy · United Kingdom | 1 | Completed | Nov 23, 2021 | 36 |
| NCT04647708Lupus Erythematosus, Systemic · Bulgaria, Germany, Moldova, Republic of and more | 1 | Completed | Dec 19, 2023 | 25 |
| NCT04448756COVID-19 · United States, Brazil, Philippines | 2 | Completed | Aug 16, 2021 | 149 |
| NCT03676322Healthy · Germany | 1 | Completed | Jul 26, 2019 | 96 |
How it is read
Names in the registry
- “M5049”, 9 entries
- “Enpatoran”, 4 entries
- “Enpatoran low dose”, 2 entries
- “Enpatoran high dose”, 2 entries
- “M5049 low dose”, 1 entry
Conditions, from the studies’ own filings
- Lupus Erythematosus, Systemic, 5 studies
- Lupus Erythematosus, Cutaneous, 1 study
- Dermatomyositis, 1 study
- Renal Insufficiency, 1 study
- COVID-19, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.